SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sbpgroup.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
EXCLUSIVE LICENSE AGREEMENT FOR TQB2102 WITH CIPLA

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ("**CTTQ**"), a subsidiary of the Company, has entered into an exclusive license and supply agreement (the "**Agreement**") with Cipla Limited ("**Cipla**") for TQB2102, also known as rolditamig deuderuxtecan, the Group's potential best-in-class HER2 bispecific antibody-drug conjugate ("**ADC**").

This is the second regional partnership for TQB2102. Together, these partnerships have generated approximately US$30 million in upfront and milestone payments for the Group, underscoring the commercial potential of the asset and the Group's disciplined regional partnering strategy.

Deal Details

Subject to the terms and conditions of the Agreement, the Group will grant Cipla an exclusive licence to develop and commercialize TQB2102 in India, South Africa and five other emerging markets ("**Licensed Territories**"). Cipla will be responsible for local clinical development, regulatory activities and commercialization in the Licensed Territories, while CTTQ will continue to manufacture and supply TQB2102.

The Group will receive an upfront payment, and is eligible for potential development, regulatory and sales milestone payments of up to US$123 million and tiered double-digit royalties based on net sales of TQB2102.

Accelerating Global Expansion and Patient Access

The Agreement advances the Group's strategy of bringing late stage innovative medicines to patients globally through carefully selected partners with strong local capabilities and market access. Cipla's established regulatory, medical and commercial presence across India, South Africa and other emerging markets provides a strong platform to accelerate the local development and regulatory approvals of TQB2102 throughout the Licensed Territories.

The collaboration is expected to support future patient access to this potential best-in-class HER2 ADC, subject to applicable regulatory approvals, while supporting the Group's international expansion and long-term value creation.

About Cipla

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 48 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 70+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Jun'26), 2nd largest in the pharma prescription market in South Africa (IQVIA MAT May'26), and 2nd largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Jun'26).

For nine decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the center of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders.

About Rolditamig Deuderuxtecan (TQB2102)

TQB2102 is a next-generation HER2 dual-epitope bispecific ADC independently developed by the Group. It simultaneously binds to the ECD II and ECD IV domains of HER2 and incorporates a cleavable linker and topoisomerase I inhibitor payload. These differentiated designs have overcome the limitations of conventional HER2 monoclonal antibodies or single-target ADCs. In particular, the dual-epitope binding mode can enhance the cross-link to receptors and endocytosis efficiency, thereby possessing clearly differentiated advantages in the treatment of patients with HER2-low expression.

At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the Group announced results from a Phase Ib clinical study of TQB2102 in HER2-low advanced breast cancer, demonstrating favorable efficacy and showing a manageable safety profile. In HER2-low patients who had received multiple prior lines of therapy (median of 4 lines of late-stage systemic therapy and 2 lines of palliative chemotherapy), the overall objective response rate (ORR) was 53.4% (39/73). Among patients who had previously progressed on ADC therapy, 44.4% achieved remission following TQB2102 treatment. In terms of safety, there was one case (0.55%) of grade 2 interstitial lung disease (ILD), with the incidence reported to be lower than that of other HER2 ADCs.

TQB2102 has received three Breakthrough Therapy Designations from the Center for Drug Evaluation of China's National Medical Products Administration. It is currently being evaluated in several Phase III clinical trials covering HER2-low, HER2-positive breast cancer, colorectal cancer and biliary tract cancer across multiple treatment settings. The Group will present the Phase III clinical study data of TQB2102 for the treatment of HER2-low breast cancer at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting as a Late-Breaking Abstract (LBA). The Group will present the Phase III clinical study data of TQB2102 for the treatment of HER2-low breast cancer at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting as a Late-Breaking Abstract (LBA).

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 31 August 2026

As at the date of this announcement, the Board of the Company comprises five executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.